痛風性関節炎(痛風):治療薬開発パイプライン分析

◆英語タイトル:Gouty Arthritis (Gout) - Pipeline Review, H2 2017
◆商品コード:GMDHC9920IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2017年11月21日
◆ページ数:95
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥220,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥660,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界における痛風性関節炎(痛風)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・痛風性関節炎(痛風)の概要
・痛風性関節炎(痛風)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・痛風性関節炎(痛風)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・痛風性関節炎(痛風)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・痛風性関節炎(痛風)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Gouty Arthritis (Gout) – Pipeline Review, H2 2017

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Gouty Arthritis (Gout) – Pipeline Review, H2 2017, provides an overview of the Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline landscape.

Gout is a type of arthritis where swelling and severe pain develops in joints, especially at the base of the big toe. Gout occurs when uric acid builds up in blood and causes inflammation in the joints. Symptoms include sudden onset of joint pain, joint swelling, heat in the affected area and joint redness. Risk factors include obesity, high alcohol intake, injury to a joint, long-standing kidney disease and high intake of foods rich in purines.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Gouty Arthritis (Gout) – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Gouty Arthritis (Gout) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gouty Arthritis (Gout) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 11, 1, 17, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Gouty Arthritis (Gout) (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Gouty Arthritis (Gout) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gouty Arthritis (Gout) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gouty Arthritis (Gout) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gouty Arthritis (Gout) (Musculoskeletal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gouty Arthritis (Gout) (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Gouty Arthritis (Gout) – Overview 6
Gouty Arthritis (Gout) – Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 11
Products under Development by Companies 12
Products under Development by Universities/Institutes 14
Gouty Arthritis (Gout) – Therapeutics Assessment 15
Assessment by Target 15
Assessment by Mechanism of Action 17
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Gouty Arthritis (Gout) – Companies Involved in Therapeutics Development 23
C&C Research Laboratories 23
CymaBay Therapeutics Inc 23
Genentech Inc 23
Immune Response BioPharma Inc 24
Jiangsu Hengrui Medicine Co Ltd 24
Monosol Rx LLC 25
Opsona Therapeutics Ltd 25
Polaris Pharmaceuticals Inc 25
Rigel Pharmaceuticals Inc 26
Swedish Orphan Biovitrum AB 26
Teijin Pharma Ltd 27
The Female Health Company 27
Wellstat Therapeutics Corp 28
XL-protein GmbH 28
Gouty Arthritis (Gout) – Drug Profiles 29
anakinra – Drug Profile 29
APP-112 – Drug Profile 32
AQB-565 – Drug Profile 33
arhalofenate – Drug Profile 34
CLX-114 – Drug Profile 39
colchicine – Drug Profile 40
D-0120 – Drug Profile 41
dapansutrile – Drug Profile 42
diacerein – Drug Profile 43
diacerein CR – Drug Profile 45
febuxostat – Drug Profile 46
FYU-981 – Drug Profile 48
HSA-Uricase – Drug Profile 49
IR-888 – Drug Profile 50
Monoclonal Antibody to Inhibit S100A9 Protein for Autoimmune Disorders, Chronic Inflammation, Neurodegenerative Diseases and Respiratory Infections – Drug Profile 51
ND-2110 – Drug Profile 52
ND-2158 – Drug Profile 53
ND-346 – Drug Profile 54
pegadricase – Drug Profile 55
Recombinant Enzyme for Gout and Tumor Lysis Syndrome – Drug Profile 59
REV-002 – Drug Profile 60
RLBN-1001 – Drug Profile 62
SHR-4640 – Drug Profile 63
Small Molecule to Inhibit IRAK1/4 for Arthritis and Psoriasis – Drug Profile 64
Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia – Drug Profile 65
Small Molecules for Gout – Drug Profile 66
Small Molecules to Inhibit GLUT9 for Gout – Drug Profile 67
Small Molecules to Inhibit Interleukin 1 Beta for Muckle-Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease and Gouty Arthritis – Drug Profile 68
Small Molecules to Inhibit NLRP3 for Gastrointestinal and Musculoskeletal Disorders – Drug Profile 69
TMX-049 – Drug Profile 70
URC-102 – Drug Profile 71
uriSHELS – Drug Profile 72
VCB-201 – Drug Profile 73
WT-2107 – Drug Profile 74
XEN-104 – Drug Profile 75
XL-400 – Drug Profile 76
Gouty Arthritis (Gout) – Dormant Projects 77
Gouty Arthritis (Gout) – Discontinued Products 79
Gouty Arthritis (Gout) – Product Development Milestones 80
Featured News & Press Releases 80
Appendix 91
Methodology 91
Coverage 91
Secondary Research 91
Primary Research 91
Expert Panel Validation 91
Contact Us 91
Disclaimer 92

List of Tables
Number of Products under Development for Gouty Arthritis (Gout), H2 2017 10
Number of Products under Development by Companies, H2 2017 12
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 13
Number of Products under Development by Universities/Institutes, H2 2017 14
Products under Development by Companies, H2 2017 15
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 16
Products under Development by Universities/Institutes, H2 2017 17
Number of Products by Stage and Target, H2 2017 19
Number of Products by Stage and Mechanism of Action, H2 2017 21
Number of Products by Stage and Route of Administration, H2 2017 23
Number of Products by Stage and Molecule Type, H2 2017 25
Gouty Arthritis (Gout) - Pipeline by C&C Research Laboratories, H2 2017 26
Gouty Arthritis (Gout) - Pipeline by CymaBay Therapeutics Inc, H2 2017 26
Gouty Arthritis (Gout) - Pipeline by Genentech Inc, H2 2017 27
Gouty Arthritis (Gout) - Pipeline by Immune Response BioPharma Inc, H2 2017 27
Gouty Arthritis (Gout) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017 28
Gouty Arthritis (Gout) - Pipeline by Monosol Rx LLC, H2 2017 28
Gouty Arthritis (Gout) - Pipeline by Opsona Therapeutics Ltd, H2 2017 28
Gouty Arthritis (Gout) - Pipeline by Polaris Pharmaceuticals Inc, H2 2017 29
Gouty Arthritis (Gout) - Pipeline by Rigel Pharmaceuticals Inc, H2 2017 29
Gouty Arthritis (Gout) - Pipeline by Swedish Orphan Biovitrum AB, H2 2017 30
Gouty Arthritis (Gout) - Pipeline by Teijin Pharma Ltd, H2 2017 30
Gouty Arthritis (Gout) - Pipeline by The Female Health Company, H2 2017 31
Gouty Arthritis (Gout) - Pipeline by Wellstat Therapeutics Corp, H2 2017 31
Gouty Arthritis (Gout) - Pipeline by XL-protein GmbH, H2 2017 31
Gouty Arthritis (Gout) - Dormant Projects, H2 2017 80
Gouty Arthritis (Gout) - Dormant Projects, H2 2017 (Contd..1), H2 2017 81
Gouty Arthritis (Gout) - Discontinued Products, H2 2017 82

List of Figures
Number of Products under Development for Gouty Arthritis (Gout), H2 2017 10
Number of Products under Development by Companies, H2 2017 11
Number of Products by Top 10 Targets, H2 2017 18
Number of Products by Stage and Top 10 Targets, H2 2017 18
Number of Products by Top 10 Mechanism of Actions, H2 2017 20
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 20
Number of Products by Routes of Administration, H2 2017 22
Number of Products by Stage and Routes of Administration, H2 2017 22
Number of Products by Molecule Types, H2 2017 24
Number of Products by Stage and Molecule Types, H2 2017 24

【レポートのキーワード】

痛風性関節炎(痛風)

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 痛風性関節炎(痛風):治療薬開発パイプライン分析(Gouty Arthritis (Gout) - Pipeline Review, H2 2017)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆